A. Description of the Advisory Firm and Types of Advisory Services Avoro Capital Advisors LLC (“AVCAP”) is a Delaware limited liability company initially formed on September 24, 2009 as venBio Select Advisor LLC. AVCAP is managed and fully controlled, by Dr. Behzad Aghazadeh. On May 3, 2019, a strategic transaction (the “Transaction”) was closed whereby venBio Select Advisor LP sold its wholly owned subsidiary, venBio Select Advisor LLC, the investment manager of the venBio Select Funds (the “Select Funds”), to a newly-formed holding company, Avoro Capital L.P. (the “Holding Company”). The Holding Company is jointly owned by Dr. Behzad Aghazadeh and Dr. Garheng Kong. Pursuant to this transaction, venBio Select Advisor LLC was renamed Avoro Capital Advisors LLC and the Select Funds were renamed Avoro Life Sciences Fund LLC and Avoro Life Sciences Offshore Fund Ltd. (our Cayman feeder fund), respectively. The Transaction did not result in any changes to the terms of the Funds Dr. Aghazadeh remains responsible for managing AVCAP, and Dr. Kong does not have day-to-day involvement in the business and affairs of AVCAP. As described further below and in response to Item 10, Dr. Kong is the founder and Managing Partner of HealthQuest Capital Management, LLC (“HealthQuest”). AVCAP provides investment advice and management to privately placed investment funds, including a Delaware limited liability company (the “Master Fund”) and a non-U.S. company (the “Feeder Fund”, together with the Master Fund, “the Avoro Life Sciences Funds”). The Feeder Fund pursues its investment activities by investing all or a portion of its assets into the Master Fund. AVCAP may decide in the future to sponsor or manage additional private investment funds and/or provide investment advisory services to separately managed accounts (collectively with the Avoro Life Sciences Funds, the “AVCAP Clients”). The AVCAP Clients’ investment objective is to achieve attractive returns with moderate risk. The AVCAP Clients invest primarily in the equity, debt and associated derivatives of companies operating in the life sciences sector and related industries. Avoro Ventures LLC (“Avoro Ventures”, collectively with AVCAP, "Avoro") is a subsidiary of the Holding Company, formed as a Delaware limited liability company on August 10, 2020. It is a partnership owned by Dr. Aghazadeh and Dr. Kong, who acts as an Advisory Partner to the new entity. Through their respective interests in

AVCAP and its general partner:
• Dr. Aghazadeh controls AVCAP and Avoro Ventures, holds a majority economic interest in Avoro Capital Advisors and Avoro Ventures, and receives certain indirect economic benefits in respect of HealthQuest; and
• Dr. Kong controls HealthQuest, holds a majority economic interest in HealthQuest, has a non- controlling, minority economic interest in Avoro Ventures, and receives certain indirect economic benefits in respect of AVCAP. Avoro Ventures is a relying adviser to AVCAP, and is the investment manager to Avoro Ventures Fund L.P. Avoro Ventures is the investment manager to the Avoro Ventures Fund L.P. (the “Ventures Fund”, collectively with the Life Sciences Funds, the "Funds", and collectively with the AVCAP Clients, the "Clients") and shall provide management and administrative services to the Ventures Fund. The Ventures Fund's investment objective is to achieve superior investment returns by making, primarily, long-term, early-stage investments in the equity and equity-related securities of healthcare companies, chiefly in the biotechnology subsector. The Ventures Fund invests primarily in privately-held companies. In select instances, investments may also be made in “value added” public companies. The Funds are offering interests (the “Interest(s)”) to certain qualified investors as described in response to Item 7. Investors in the Funds, including prospective investors, are referred to herein as “Investors”. Avoro's strategy and the risks involved are described in response to Item 8, below. B. Client Tailored Services and Client Imposed Restrictions Advisory services are tailored to achieve the Clients’ investment objectives as described more fully in each Fund’s offering and governing documents (the “Constituent Documents”). Generally, the Firm has the authority to select which and how many securities and other instruments to buy or sell without consultation with the Clients or their Investors. C. Wrap Fee Programs The Firm does not participate in wrap-fee programs. D. Amounts under Management As of December 31, 2023, Avoro had approximately $5,637,948,177 in net assets under management: Discretionary Amounts: Non-Discretionary Amounts: Date Calculated: $5,637,948,177 $0 December 31, 2023 Please note that the figure above reflects the net asset value of the AVCAP Clients, as well as the Avoro Ventures Fund net asset value plus uncalled capital commitments.